MediPharm Labs Corp.

TSX:LABS Voorraadrapport

Marktkapitalisatie: CA$28.8m

MediPharm Labs Beheer

Beheer criteriumcontroles 3/4

De CEO MediPharm Labs is David Pidduck, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 1.31M, bestaande uit 36% salaris en 64% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.08% van de aandelen van het bedrijf, ter waarde CA$ 1.17M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 5.4 jaar.

Belangrijke informatie

David Pidduck

Algemeen directeur

CA$1.3m

Totale compensatie

Percentage CEO-salaris36.0%
Dienstverband CEO2.6yrs
Eigendom CEO4.1%
Management gemiddelde ambtstermijn5.1yrs
Gemiddelde ambtstermijn bestuur5.4yrs

Recente managementupdates

Recent updates

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

Oct 11
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29
MediPharm Labs (TSE:LABS) Is Using Debt Safely

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Analyse CEO-vergoeding

Hoe is David Pidduck's beloning veranderd ten opzichte van MediPharm Labs's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-CA$12m

Jun 30 2024n/an/a

-CA$13m

Mar 31 2024n/an/a

-CA$14m

Dec 31 2023CA$1mCA$470k

-CA$13m

Sep 30 2023n/an/a

-CA$16m

Jun 30 2023n/an/a

-CA$20m

Mar 31 2023n/an/a

-CA$26m

Dec 31 2022CA$3mCA$315k

-CA$30m

Compensatie versus markt: De totale vergoeding ($USD 934.30K ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 169.25K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Pidduck

2.6yrs

Tenure

CA$1,305,051

Compensatie

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Pidduck
CEO & Director2.6yrsCA$1.31m4.08%
CA$ 1.2m
Keith Strachan
Co-Founder & President5.8yrsCA$819.48k2.17%
CA$ 624.2k
Greg Hunter
Chief Financial Officer3.8yrsCA$957.75k0.31%
CA$ 90.5k
Patrick McCutcheon
Founder9.8yrsCA$858.16kgeen gegevens
Brett Moon
Vice President of Sales4.5yrsgeen gegevensgeen gegevens
Kirk Binns
Executive Vice President of Global Accounts5.8yrsgeen gegevensgeen gegevens

5.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van LABS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Pidduck
CEO & Director2.6yrsCA$1.31m4.08%
CA$ 1.2m
Shelley Martin
Independent Director4.4yrsCA$64.49k0.020%
CA$ 5.6k
Michael Bumby
Independent Director1.6yrsCA$34.45k0.050%
CA$ 14.4k
Christopher Taves
Independent Chairman of the Board4.3yrsCA$87.14k0.35%
CA$ 99.6k
Miriam McDonald
Member of the Science Advisory Board5.6yrsCA$32.40kgeen gegevens
Leslie Brown
Member of the Science Advisory Board5.6yrsgeen gegevensgeen gegevens
Matt Archibald
Member of the Science Advisory Board5.6yrsgeen gegevensgeen gegevens
Markus Roggen
Member of the Science Advisory Board5.6yrsgeen gegevensgeen gegevens
Arshad Hack
Member of the Science Advisory Board5.6yrsgeen gegevensgeen gegevens
Jerry King
Member of the Science Advisory Board5.6yrsgeen gegevensgeen gegevens
Carolina Landolt-Marticorena
Member of the Science Advisory Board5.3yrsgeen gegevensgeen gegevens
Christopher Halyk
Independent Director4.3yrsCA$56.05k0.043%
CA$ 12.3k

5.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van LABS wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).